印度人群紫杉醇所致周围神经病变发生率及严重程度的前瞻性研究

Anju M George, A. M A, Sharon K Joseph, A. Philip, R. Reghu, Krupa Merin Sam
{"title":"印度人群紫杉醇所致周围神经病变发生率及严重程度的前瞻性研究","authors":"Anju M George, A. M A, Sharon K Joseph, A. Philip, R. Reghu, Krupa Merin Sam","doi":"10.2174/1573394718666220610185525","DOIUrl":null,"url":null,"abstract":"\n\nIn spite of the high efficacy rate of paclitaxel, physicians are compelled to discontinue the regimen due to its prevailing neurotoxicity and myelosuppressive effects, thus not being able to achieve the desired clinical outcomes. The neurotoxicity studies of paclitaxel have been mostly done on upper dose limits (>275mg/m2), and little information is available on lower doses. Since there is a lack of such studies in the Indian population, the medical professionals are unable to analyze at what cumulative dose does paclitaxel show maximum severity of peripheral neuropathy.\n\n\n\nThis is a prospective observational study conducted for a period of 1 year in patients undergoing paclitaxel therapy. These patients were evaluated for the incidence and severity of paclitaxel induced peripheral neuropathy during the first 6 cycles using the QLQ-CIPN questionnaire. We also identified the cumulative dose at which most patients developed peripheral neuropathy and each patient’s quality of life using EORTC QLQ C30.\n\n\n\nOut of 85 patients, 76 developed peripheral neuropathy during the first 6 cycles. It was observed that the severity of peripheral neuropathy was increasing in each cycle of therapy. The overall quality of life of patients was decreasing with therapy, and at a cumulative dose of 525mg/m2 most of the patients (40%) developed symptoms of peripheral neuropathy.\n\n\n\nThe incidence and severity of peripheral neuropathy increased with each cycle, and this has led to a significant reduction in the quality of life of patients post 6 cycles; and also, a high cumulative dose may limit the paclitaxel therapy.\n","PeriodicalId":43754,"journal":{"name":"Current Cancer Therapy Reviews","volume":" ","pages":""},"PeriodicalIF":0.4000,"publicationDate":"2022-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A prospective study on the incidence and severity of paclitaxel induced peripheral neuropathy in indian population\",\"authors\":\"Anju M George, A. M A, Sharon K Joseph, A. Philip, R. Reghu, Krupa Merin Sam\",\"doi\":\"10.2174/1573394718666220610185525\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n\\nIn spite of the high efficacy rate of paclitaxel, physicians are compelled to discontinue the regimen due to its prevailing neurotoxicity and myelosuppressive effects, thus not being able to achieve the desired clinical outcomes. The neurotoxicity studies of paclitaxel have been mostly done on upper dose limits (>275mg/m2), and little information is available on lower doses. Since there is a lack of such studies in the Indian population, the medical professionals are unable to analyze at what cumulative dose does paclitaxel show maximum severity of peripheral neuropathy.\\n\\n\\n\\nThis is a prospective observational study conducted for a period of 1 year in patients undergoing paclitaxel therapy. These patients were evaluated for the incidence and severity of paclitaxel induced peripheral neuropathy during the first 6 cycles using the QLQ-CIPN questionnaire. We also identified the cumulative dose at which most patients developed peripheral neuropathy and each patient’s quality of life using EORTC QLQ C30.\\n\\n\\n\\nOut of 85 patients, 76 developed peripheral neuropathy during the first 6 cycles. It was observed that the severity of peripheral neuropathy was increasing in each cycle of therapy. The overall quality of life of patients was decreasing with therapy, and at a cumulative dose of 525mg/m2 most of the patients (40%) developed symptoms of peripheral neuropathy.\\n\\n\\n\\nThe incidence and severity of peripheral neuropathy increased with each cycle, and this has led to a significant reduction in the quality of life of patients post 6 cycles; and also, a high cumulative dose may limit the paclitaxel therapy.\\n\",\"PeriodicalId\":43754,\"journal\":{\"name\":\"Current Cancer Therapy Reviews\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2022-06-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Cancer Therapy Reviews\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/1573394718666220610185525\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Cancer Therapy Reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1573394718666220610185525","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

尽管紫杉醇的有效率很高,但由于其普遍存在的神经毒性和骨髓抑制作用,医生不得不停止该方案,从而无法达到预期的临床结果。紫杉醇的神经毒性研究大多是在上限剂量(约275mg/m2)上进行的,关于较低剂量的资料很少。由于在印度人群中缺乏这样的研究,医学专业人员无法分析紫杉醇在多大的累积剂量下会显示周围神经病变的最大严重程度。这是一项对接受紫杉醇治疗的患者进行为期1年的前瞻性观察研究。使用QLQ-CIPN问卷评估前6个周期紫杉醇诱导周围神经病变的发生率和严重程度。我们还使用EORTC QLQ C30确定了大多数患者发生周围神经病变的累积剂量和每个患者的生活质量。85例患者中,76例在前6个周期发生周围神经病变。观察到周围神经病变的严重程度随治疗周期的增加而增加。患者的整体生活质量随着治疗而下降,在525mg/m2的累积剂量下,大多数患者(40%)出现周围神经病变症状。周围神经病变的发生率和严重程度随着每个周期的增加而增加,这导致患者在6个周期后的生活质量显著下降;而且,高累积剂量可能会限制紫杉醇治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
A prospective study on the incidence and severity of paclitaxel induced peripheral neuropathy in indian population
In spite of the high efficacy rate of paclitaxel, physicians are compelled to discontinue the regimen due to its prevailing neurotoxicity and myelosuppressive effects, thus not being able to achieve the desired clinical outcomes. The neurotoxicity studies of paclitaxel have been mostly done on upper dose limits (>275mg/m2), and little information is available on lower doses. Since there is a lack of such studies in the Indian population, the medical professionals are unable to analyze at what cumulative dose does paclitaxel show maximum severity of peripheral neuropathy. This is a prospective observational study conducted for a period of 1 year in patients undergoing paclitaxel therapy. These patients were evaluated for the incidence and severity of paclitaxel induced peripheral neuropathy during the first 6 cycles using the QLQ-CIPN questionnaire. We also identified the cumulative dose at which most patients developed peripheral neuropathy and each patient’s quality of life using EORTC QLQ C30. Out of 85 patients, 76 developed peripheral neuropathy during the first 6 cycles. It was observed that the severity of peripheral neuropathy was increasing in each cycle of therapy. The overall quality of life of patients was decreasing with therapy, and at a cumulative dose of 525mg/m2 most of the patients (40%) developed symptoms of peripheral neuropathy. The incidence and severity of peripheral neuropathy increased with each cycle, and this has led to a significant reduction in the quality of life of patients post 6 cycles; and also, a high cumulative dose may limit the paclitaxel therapy.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
1.00
自引率
0.00%
发文量
50
期刊介绍: Current Cancer Therapy Reviews publishes frontier reviews on all the latest advances in clinical oncology, cancer therapy and pharmacology. The journal"s aim is to publish the highest quality review articles dedicated to clinical research in the field. The journal is essential reading for all researchers and clinicians in cancer therapy.
期刊最新文献
Understanding the Challenges Associated with Approval of Anticancer Products to Facilitate the Regulatory Approvals: A Cross-sectional Study Bibliometric Analysis to Improve Combined Treatment Strategies for Glioblastoma in America Odor generation pattern of swine manure according to the processing form of feed. Childhood Heart Tumors: Detection, Diagnosis, and Treatments Metformin (The Miracle Drug) Kinetics in Different Diseases such as Cancer
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1